{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:10Z","timestamp":1792782550875,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Scientific and Technological Committee","award":["22S21902000"],"award-info":[{"award-number":["22S21902000"]}]},{"name":"Special fund for clinical research of Wu Jieping Medical Foundation","award":["320.6750.2021-2-75"],"award-info":[{"award-number":["320.6750.2021-2-75"]}],"id":[{"id":"https:\/\/ror.org\/05dgwj702","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Special fund for clinical research of Bai Qiuen Medical Foundation","award":["Z04JKM2021005"],"award-info":[{"award-number":["Z04JKM2021005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05872-y","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:26:47Z","timestamp":1789784807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials"],"prefix":"10.1007","author":[{"given":"Xinping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijier","family":"Qiaolongbatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-9689","authenticated-orcid":false,"given":"Zhenghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"9","key":"5872_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","volume":"171","author":"A Azuma","year":"2005","unstructured":"Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171(9):1040\u20131047. https:\/\/doi.org\/10.1164\/rccm.200404-571OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"5872_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70497","volume":"16","author":"H Babariya","year":"2024","unstructured":"Babariya H, Gaidhane SA, Acharya S et al (2024) Pirfenidone as a cornerstone in the management of fibrotic interstitial lung diseases and its emerging applications: a comprehensive review. Cureus 16(9):e70497. https:\/\/doi.org\/10.7759\/cureus.70497","journal-title":"Cureus"},{"key":"5872_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2015.03.007","volume":"32","author":"L Calzetta","year":"2015","unstructured":"Calzetta L, Cazzola M, Page CP et al (2015) Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3\/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther 32:15\u201323. https:\/\/doi.org\/10.1016\/j.pupt.2015.03.007","journal-title":"Pulm Pharmacol Ther"},{"key":"5872_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejphar.2014.10.025","volume":"745","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Calzetta L, Page CP et al (2014) Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol 745:135\u2013143. https:\/\/doi.org\/10.1016\/j.ejphar.2014.10.025","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"5872_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","volume":"168","author":"HR Collard","year":"2003","unstructured":"Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK (2003) Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168(5):538\u2013542. https:\/\/doi.org\/10.1164\/rccm.200211-1311OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5872_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","volume":"58","author":"E Conte","year":"2014","unstructured":"Conte E, Gili E, Fagone E et al (2014) Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58:13\u201319. https:\/\/doi.org\/10.1016\/j.ejps.2014.02.014","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"5872_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12325-014-0112-1","volume":"31","author":"U Costabel","year":"2014","unstructured":"Costabel U, Bendstrup E, Cottin V et al (2014) Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 31(4):375\u2013391. https:\/\/doi.org\/10.1007\/s12325-014-0112-1","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"5872_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1465-9921-14-s1-s5","volume":"14","author":"V Cottin","year":"2013","unstructured":"Cottin V (2013) The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 14(Suppl 1):S5. https:\/\/doi.org\/10.1186\/1465-9921-14-s1-s5","journal-title":"Respir Res"},{"issue":"4","key":"5872_CR9","doi-asserted-by":"publisher","first-page":"00084","DOI":"10.1183\/23120541.00084-2018","volume":"4","author":"V Cottin","year":"2018","unstructured":"Cottin V, Koschel D, Gunther A et al (2018) Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res 4(4):00084. https:\/\/doi.org\/10.1183\/23120541.00084-2018","journal-title":"ERJ Open Res"},{"issue":"6","key":"5872_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/1060028020964451","volume":"55","author":"E Di Martino","year":"2021","unstructured":"Di Martino E, Provenzani A, Vitulo P et al (2021) Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 55(6):723\u2013731. https:\/\/doi.org\/10.1177\/1060028020964451","journal-title":"Ann Pharmacother"},{"issue":"2","key":"5872_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12949","volume":"76","author":"M Ha","year":"2024","unstructured":"Ha M, Yoon D, Lee C et al (2024) Investigating the safety profiles of exogenous melatonin and associated adverse events: a pharmacovigilance study using WHO-VigiBase. J Pineal Res 76(2):e12949. https:\/\/doi.org\/10.1111\/jpi.12949","journal-title":"J Pineal Res"},{"issue":"12","key":"5872_CR12","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.Can-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12):4774\u20134782. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6307","journal-title":"Cancer Res"},{"issue":"10","key":"5872_CR13","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2665-9913(22)00215-6","volume":"4","author":"AM Hoffmann-Vold","year":"2022","unstructured":"Hoffmann-Vold AM, Volkmann ER, Allanore Y et al (2022) Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials. Lancet Rheumatol 4(10):e679\u2013e687. https:\/\/doi.org\/10.1016\/S2665-9913(22)00215-6","journal-title":"Lancet Rheumatol"},{"issue":"42","key":"5872_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001600","volume":"94","author":"H Huang","year":"2015","unstructured":"Huang H, Dai H, Kang J, Chen B, Sun T, Xu Z (2015) Double-blind randomized trial of pirfenidone in chinese idiopathic pulmonary fibrosis patients. Medicine (Baltimore) 94(42):e1600. https:\/\/doi.org\/10.1097\/MD.0000000000001600","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"5872_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040813","volume":"14","author":"T Huang","year":"2022","unstructured":"Huang T, Gao J, Cai L et al (2022) Treating pulmonary fibrosis with non-viral gene therapy: from bench to bedside. Pharmaceutics 14(4):813. https:\/\/doi.org\/10.3390\/pharmaceutics14040813","journal-title":"Pharmaceutics"},{"key":"5872_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40801-023-00396-w","volume":"11","author":"K Iwasaki","year":"2023","unstructured":"Iwasaki K, Wakabayashi H, Saiki A et al (2023) Real-world clinical efficacy of antifibrotic agents for idiopathic pulmonary fibrosis: a single-center retrospective study in Japan. Drugs Real World Outcomes 11:45\u201354. https:\/\/doi.org\/10.1007\/s40801-023-00396-w","journal-title":"Drugs Real World Outcomes"},{"key":"5872_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40248-018-0158-z","volume":"13","author":"LH Lancaster","year":"2018","unstructured":"Lancaster LH (2018) Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 13:45. https:\/\/doi.org\/10.1186\/s40248-018-0158-z","journal-title":"Multidiscip Respir Med"},{"key":"5872_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04733-4","author":"L Lin","year":"2025","unstructured":"Lin L, Chen M, Chen H (2025) Real-world safety profile of opicapone: a comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04733-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"5872_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA et al (2021) Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22(7):3765. https:\/\/doi.org\/10.3390\/ijms22073765","journal-title":"Int J Mol Sci"},{"key":"5872_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17534666231181537","volume":"17","author":"TH Mai","year":"2023","unstructured":"Mai TH, Han LW, Hsu JC et al (2023) Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective. Ther Adv Respir Dis 17:17534666231181537. https:\/\/doi.org\/10.1177\/17534666231181537","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"5872_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10753-018-0871-y","volume":"42","author":"JL Medina","year":"2019","unstructured":"Medina JL, Sebastian EA, Fourcaudot AB et al (2019) Pirfenidone ointment modulates the burn wound bed in C57BL\/6 mice by suppressing inflammatory responses. Inflammation 42(1):45\u201353. https:\/\/doi.org\/10.1007\/s10753-018-0871-y","journal-title":"Inflammation"},{"issue":"5","key":"5872_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/mcp.0000000000000091","volume":"20","author":"SD Nathan","year":"2014","unstructured":"Nathan SD, Meyer KC (2014) IPF clinical trial design and endpoints. Curr Opin Pulm Med 20(5):463\u2013471. https:\/\/doi.org\/10.1097\/mcp.0000000000000091","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"5872_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","volume":"190","author":"M Natsuizaka","year":"2014","unstructured":"Natsuizaka M, Chiba H, Kuronuma K et al (2014) Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190(7):773\u2013779. https:\/\/doi.org\/10.1164\/rccm.201403-0566OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5872_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04746-z","author":"R Nie","year":"2025","unstructured":"Nie R, Yu B, Li Q et al (2025) Hepatobiliary disorders associated with triazole antifungal agents: a disproportionality and Bayesian analysis based on the FAERS database. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04746-z","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9779","key":"5872_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760\u20131769. https:\/\/doi.org\/10.1016\/S0140-6736(11)60405-4","journal-title":"Lancet"},{"key":"5872_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-024-03079-2","volume":"42","author":"T Ogura","year":"2025","unstructured":"Ogura T, Inoue Y, Azuma A et al (2025) Real-world safety and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of a post-marketing surveillance in Japan. Adv Ther 42:1075\u20131093. https:\/\/doi.org\/10.1007\/s12325-024-03079-2","journal-title":"Adv Ther"},{"issue":"1\u20133","key":"5872_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590(1\u20133):400\u2013408. https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.046","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"5872_CR28","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"issue":"3","key":"5872_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/ejcdt.ejcdt_140_19","volume":"69","author":"AAEA Sadon","year":"2020","unstructured":"Sadon AAEA, Kenawy AS, Abdelsalam AH et al (2020) Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects. Egypt J Chest Dis Tuberc 69(3):549\u2013559. https:\/\/doi.org\/10.4103\/ejcdt.ejcdt_140_19","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"7","key":"5872_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K et al (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"5872_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jphotobiol.2013.01.010","volume":"120","author":"Y Seto","year":"2013","unstructured":"Seto Y, Inoue R, Kato M et al (2013) Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B 120:44\u201351. https:\/\/doi.org\/10.1016\/j.jphotobiol.2013.01.010","journal-title":"J Photochem Photobiol B"},{"key":"5872_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105635","volume":"169","author":"MY Sun","year":"2021","unstructured":"Sun MY, Sun YY, Feng ZR et al (2021) New insights into the Hippo\/YAP pathway in idiopathic pulmonary fibrosis. Pharmacol Res 169:105635. https:\/\/doi.org\/10.1016\/j.phrs.2021.105635","journal-title":"Pharmacol Res"},{"key":"5872_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/PPA.S37233","volume":"8","author":"Y Takeda","year":"2014","unstructured":"Takeda Y, Tsujino K, Kijima T et al (2014) Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence 8:361\u2013370. https:\/\/doi.org\/10.2147\/PPA.S37233","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"5872_CR34","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y et al (2010) Pirfenidone in idiopathic pulmonary fibrosis: a Phase III clinical trial inJapan. Eur Respir J 35(4):821\u2013829. https:\/\/doi.org\/10.1183\/09031936.00005209","journal-title":"Eur Respir J"},{"issue":"2","key":"5872_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/1346-8138.13009","volume":"43","author":"A Tsuruta","year":"2016","unstructured":"Tsuruta A, Washio K, Fukunaga A et al (2016) Pirfenidone-induced photoleukomelanoderma in a patient with idiopathic pulmonary fibrosis. J Dermatol 43(2):207\u2013209. https:\/\/doi.org\/10.1111\/1346-8138.13009","journal-title":"J Dermatol"},{"issue":"2","key":"5872_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/14656566.2018.1425681","volume":"19","author":"F Varone","year":"2018","unstructured":"Varone F, Sgalla G, Iovene B et al (2018) Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 19(2):167\u2013175. https:\/\/doi.org\/10.1080\/14656566.2018.1425681","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"5872_CR37","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1434\u20131445. https:\/\/doi.org\/10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"5872_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04642-6","author":"J Zhou","year":"2025","unstructured":"Zhou J, Cai R, Niu P et al (2025) Venous thromboembolism events associated with tofacitinib in rheumatoid arthritis patients: a real-world study from FAERS database. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04642-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05872-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05872-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05872-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:26:49Z","timestamp":1789784809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05872-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":38,"alternative-id":["5872"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05872-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}